FGF-23 levels in patients with AKI and risk of adverse outcomes.

ABSTRACT:

Background and objectives

Fibroblast growth factor 23 plays an important role in regulating phosphate and vitamin D homeostasis. Elevated levels of fibroblast growth factor 23 are independently associated with mortality in patients with CKD and ESRD. Whether fibroblast growth factor 23 levels are elevated and associated with adverse outcomes in patients with AKI has not been studied.

Design, setting, participants, & measurements

This study had 30 participants with AKI, which was defined as an increase in serum creatinine ≥ 0.3 mg/dl or ≥ 50% from baseline, and 30 controls from the general hospital wards and intensive care units. Plasma levels of C-terminal fibroblast growth factor 23 and vitamin D metabolites were measured within 24 hours of AKI onset and 5 days later. The c

SUBMITTER: Leaf DE 

PROVIDER: S-EPMC3408118 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature